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Captopril inhibits tumour growth in a xenograft model of
human renal cell carcinoma
S-I Hii, DL Nicol, DC Gotley, LC Thompson, MK Green and JR Jonsson
Department of Surgery, University of Queensland, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia
Summary The effect of captopril on tumour growth was examined in a xenograft model of human renal cell carcinoma (RCC). Inoculation of
the human RCC cell line SN12K-1 (106 cells) under the left kidney capsule of severe combined immunodeficient (SCID) mice resulted in the
growth of large tumours, with an increase in weight of the inoculated kidney of 3.69 ± 1.63-fold (mean ± s.d.) when compared with the
contralateral normal kidney. In mice treated with captopril (19 mg kg-1 day-' or 94 mg kg-1 day-1 administered in the drinking water), there was
a significant dose-related reduction in tumour development; the tumour bearing kidneys weighed 1.9± 0.42 and 1.55± 0.42 times the normal
kidneys, respectively (P< 0.05 compared with untreated animals). In vitro, captopril at clinically achievable doses (0.1-10 ,UM) had no
significant effect on the incorporation of [3H]thymidine into SN12K-1 cells. Thus, this highly significant attenuation by captopril of in vivo
tumour growth does not appear to be due to a direct effect on the proliferation of the tumour cells. Further studies are required to determine
the mechanism of inhibition of tumour growth by captopril, in particular to evaluate the role of angiotensin 11 in this process.
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Renal cell carcinoma (RCC) is the most common malignancy
arising in the adult kidney. It accounts for 2% of all malignancies
as well as 2% of overall cancer deaths (Mancilla-Jimenez et al,
1976). Currently, radical nephrectomy remains the only effective
means of treatment for localized RCC, whereas metastatic spread
is infrequently amenable to surgery and most patients die within 1
year of diagnosis. Treatment modalities including radiotherapy,
chemotherapy and immunotherapy, which have proven efficacy
in other malignancies, rarely alter the natural history of RCC.
Treatment of systemic disease with chemotherapy and
immunotherapy are both associated with significant toxicity and
morbidity.
RCCs are solid tumours arising from the proximal convoluted
tubules of the kidney. Tumour growth is critically dependent on
abundant neovascularization mediated by vasculogenic cytokines
produced by tumour cells (Folkman and Klagsbum, 1987). As a
consequence of this neovascularization alterations in renal blood
flow occur with RCC.
The renin angiotensin system (RAS) regulates normal kidney
blood flow and fluidhomeostasis, and alsoplays akey role inblood
pressure control (Pfeffer etal, 1992; Burris, 1995). Renin, produced
by the juxtaglomerular apparatus, cleaves angiotensinogen to
angiotensin I (ATI). Angiotensin-converting enzyme (ACE) results
in the subsequent production ofthe active compound angiotensin II
(ATII). Although the reaction catalysed by renin is substrate
specific, a number ofsubstrates are reported to be cleaved by ACE.
These include bradykinin and substance P. The actions ofATII are
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mediated through cell-surface membrane receptors. Within the
kidney ATII receptors are expressed in vascular, glomerular and
tubular structures (Douglas, 1987). The ATII receptors are also
expressed in RCC (Goldfarb et al, 1994). However, the role ofATII
and its receptors in RCC has yet to be defined.
Captopril (D-3-mercapto-2-methylpropanoyl-L-proline) is an
orally active inhibitor ofACE that is widely used as an antihyper-
tensive agent. In addition to its bloodpressure-lowering properties,
captopril dramatically reduces the cardiac and vascular hyper-
trophy that accompanies prolonged hypertension, an effect not
seen with otherantihypertensive agents such as a-antagonists or ,B
blockers (Antonaccio et al, 1979; Giudicelli et al, 1981; Jonsson et
al, 1992). Although chronic administration of captopril to young
rats (from 4 to 12 weeks of age) results in the development of a
restricted and fragile vasculature, the vascular effects of captopril
when administered to adult rats are less pronounced
(J Jonsson, personal observation). This would suggest that
captopril may influence angiogenesis without conspicuous effects
on established blood vessels.
In this study we examined the effect ofcaptopril on the growth
ofhuman RCC in vitro and in an orthotopic xenograft model.
MATERIALS AND METHODS
Animals
Male severe combined immunodeficient (SCID) mice were
purchased at 7 weeks ofage from Animal Resources Centre, Perth,
Australia. The mice were kept in a temperature-controlled, specific
pathogen-free room (23°C; 12 hlight-dark regime) and were given
free access to the standard diet (Norco, Lismore, NSW, Australia).
The experiments were started when the animals were 8 weeks of
age. The study was approved by the Group 5 Animal Experimental
Ethics Committee, Queensland University, Australia.
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Figure 1 Kidneys inoculated with SN12K-1 cells (upper) and coi
normal kidneys (lower) from control mice (left) and mice treated w
(94 mg kg-' day-') (right)
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Figure 2 Relative increase in kidney weight 6 weeks after inoculation with
SN12K-1 cells under the left kidney capsule in control mice and mice that
received captopril (19 or 94 mg kg-' day-'). **P < 0.01; ***P < 0.001 (ANOVA)
Xenograft model of human RCC
The human RCC cell line, SN12K-1, derived from a male
Caucasian RCC patient with lung metastasis was a generous gift
from Dr Isaiah Fidler, Houston, TX, USA. Cells were cultured in
RPMI-1640 medium (Gibco) containing 25 mM Hepes that was
supplemented with 10% fetal calfserum (FCS, Gibco), 100 U ml
penicillin, 100 ,ug ml' streptomycin (ICN) and 2 mM L-glutamine
(ICN) (complete medium). Before xenografting into the mouse,
SN12K-1 cells reaching confluence were trypsinized using 0.25%
trypsin EDTA (Gibco) and washed twice with sterile 1 x phos-
phate-buffered saline (PBS), pH 7.0. Cell viability was assessedby
trypan blue exclusion and was always greater than 98%.
One million viable SN12K-1 cells were inoculated subcapsu-
larly into the left kidney of each mouse. Six weeks after inocula-
tion, the mice were killed and examined for tumour growth.
Tumour burden was assessed by comparing the weight of the
kidney into which RCC cells were implanted to the animal's
normal contralateral kidney.
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Figure 3(A) Effect of captopril (0-10 mm) on the in vitro proliferation of
SN12K-1 cells, as assessed by [3H]thymidine incorporation. P< 0.01
(ANOVA). (B) Effect of captopril on the growth curve of SN12K-1 cells
(0, control; captopril: 0, 0.1 gM; , 1 gM; A, 10gM; A, 100gM; 0, 1 mM;
*, 10 mM. **P< 0.01, ***P < 0.001 (ANOVA)
Drug treatment
After inoculation, mice (n = 6 in each group) were treated with
captopril (19 mg kg-' day-' or 94 mg kg-' day-1) in the drinking
water for 6 weeks. Drinking water containing freshly prepared
captopril was changed three times a week. No captopril was given
in the control group.
In vitro cell proliferation assays
To assess the direct effect ofcaptopril on cell proliferation, 2 x 104
viable SN12K-1 cells were cultured (96-well flat-bottomed
microtitre plates) in complete medium in the presence ofcaptopril
(0-10 mM). After 48 h of culture (5% carbon dioxide, 95%
humidity), 1 ,uCi of [3H]thymidine was added to each well. Sixteen
hours later the cells were harvested, and the amount of [3H]thymi-
dine incorporated was measured by scintillation counting. Six
replicate wells were assessed for each captopril concentration, and
the results were expressed as the mean c.p.m. ofthe six replicates.
To assess the affect ofcaptopril on the growth curve of SN12K-
1 cells, 2 x 104 viable SN12K-1 cells were cultured in complete
medium in the presence ofcaptopril (0-10 mM) and the number of
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cells counted at 24, 36 and 48 h after initiation of the culture.
Before counting, the cells were trypsinized using 0.25% trypsin
EDTA (Gibco) and washed once with sterile 1 x PBS, pH 7.0. Cell
viability was assessed by trypan blue exclusion and was greater
than 98% for all captopril concentrations except 10 mm. Three
replicate wells were assessed for each captopril concentration at
each time point and the results expressed as the mean cell number
ofthe three replicates.
Statistical analyses
Data are expressed as means ± s.d. Differences between groups
was assessed by analysis of variance (ANOVA), with P < 0.05
regarded as statistically significant.
RESULTS
Inoculation of the left kidney of SCID mice resulted in the devel-
opment oflarge tumours (Figure 1) with a mean increase in kidney
weight 3.69 ± 1.63-fold.
In those mice administered captopril in the drinking water
(19 mg kg-' day-' or 94 mg kg-' day-'), tumour growth was signifi-
cantly reduced when compared with control mice (Figure 1). The
tumour bearing kidneys in captopril treated mice weighed only
1.9 ± 0.42 and 1.55 ± 0.42 times the normal kidneys in the
19 mg kg-' day-' or 94 mg kg-' day-' groups respectively (P < 0.05,
ANOVA) (Figure 2). Captopril treatment had no observable
detrimental side-effects.
The direct effect of captopril on the proliferation of SN12K-I
cells was assessed by [3H]thymidine incorporation during in vitro
culture. Captopril at clinically achievable concentrations (0.1-
10 ,UM) had no significant effect on [3H]thymidine incorporation
(Figure 3A). At concentrations higher than those clinically achiev-
able (30 ,UM-3 mM), captopril inhibited SN12K-I cell proliferation
by 14-31%. At 10 mm, a direct cytotoxic effect was observed that
resulted in cell detachment and death within 48 h ofculture initia-
tion. In addition, clinically achievable concentrations of captopril
(O.1-1I00 gM) did not significantly affect the growth curve of
SN12K-1 cells (Figure 3B).
DISCUSSION
In the present study, the ACE inhibitor captopril was found to
inhibit tumour growth in human RCC in a SCID mouse model.
Significant reduction in tumour size was observed after orthotopic
implantation ofhuman RCC in captopril-treated animals compared
with controls. This would not appear to be a direct effect as prolif-
eration of RCC cells in culture was not inhibited by clinically
achievable concentrations of captopril. An indirect effect of capto-
pril, possibly as a consequence ofreduction in ATII activity, would
therefore appear responsible for the reduction in tumour size.
ATII has diverse effects on the proximal tubular cells from
which RCCs arise. It modifies fluid and electrolyte reabsorption
(Cogan, 1990; Harris, 1992) and exerts metabolic effects including
gluconeogenesis and ammonia production (Chobanian and Julin,
1987; Goligorsky et al, 1987; Johnston et al, 1993). In vitro ATII
induces hypertrophy of proximal tubular cells (Wolf and Neilson,
1990; Harris, 1992; Wolf et al, 1993; Wolf, 1993) and potentiates
the mitogenic effects of epidermal growth factor (Norman et al,
1987). It also induces the cellular oncogenes c-myc, c-fos, and c-N-
ras (Wolf and Neilson, 1990), as well as growth factors such as
TGF-1 (Wolf et al, 1995). Therefore, captopril may have an
antiproliferative effect on RCC through a reduction ofATII-stimu-
lated production of growth factors or cytokines. Conversely, as
ACE catalyses the cleavage of substrates other than ATII, the
observed effect of captopril may be independent of the actions of
ATII. Further studies using specific ATII-receptor antagonists in
our animal model will determine whether the inhibition of tumour
growth by captopril involves the RAS.
The tumour inhibitory effects of captopril may not be renal
specific. Chemically-induced hepatic tumours in rats (Volpert et al,
1996) and pancreatic duct carcinoma in hamsters (Reddy et al,
1995) have also recently been shown to be dramatically reduced
with captopril. This appears to be due to inhibition of mitosis as
the proliferation of preneoplastic cells was reduced by captopril
before actual tumour formation.
Less direct effects of ATII include vascular changes associated
with hypertension and, specifically, contraction, increased protein
synthesis and hypertrophy of vascular smooth muscle cells. It may
also have a role in neovascularization. Recent studies have shown
ATII-dependent stimulation of angiogenesis in experimental models
(Fernandez et al, 1985; Le Noble et al, 1991; 1993) and enhanced
vessel density in muscle tissue (Hemandez et al, 1992). Captopril has
been shown previously to be an effective inhibitorofangiogenesis. In
the rat, it inhibits aortic and microvascular growth and prevents
induction of corneal neovascularization (Volpert et al, 1996). In
culture it inhibits vascular endothelial cell migration and collagenase
production, which are both critical to angiogenesis in vivo. These
endothelial cell effects appearindependent ofACE inhibition and are
not seen with other ACE inhibitors (Volpert et al, 1996).
In conclusion, we have demonstrated growth inhibition of RCC
by captopril. Future studies are required to determine if this is
mediated through the renin-angiotensin system and whether it is a
consequence of inhibition of cell proliferation or tumour neovas-
cularization. Clinical studies would appear to be needed to deter-
mine whether captopril may have a role as an adjuvant to surgical
treatment for RCC.
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